Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer.

Li Q, Chen Y, Zhang D, Grossman J, Li L, Khurana N, Jiang H, Grierson PM, Herndon J, DeNardo DG, Challen GA, Liu J, Ruzinova MB, Fields RC, Lim KH.

JCI Insight. 2019 Oct 3;4(19). pii: 130867. doi: 10.1172/jci.insight.130867.

2.

Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles.

Strand MS, Krasnick BA, Pan H, Zhang X, Bi Y, Brooks C, Wetzel C, Sankpal N, Fleming T, Goedegebuure SP, DeNardo DG, Gillanders WE, Hawkins WG, Wickline SA, Fields RC.

Oncotarget. 2019 Jul 30;10(46):4761-4775. doi: 10.18632/oncotarget.27109. eCollection 2019 Jul 30.

3.

A Single-Cell Window into Pancreas Cancer Fibroblast Heterogeneity.

Belle JI, DeNardo DG.

Cancer Discov. 2019 Aug;9(8):1001-1002. doi: 10.1158/2159-8290.CD-19-0576.

PMID:
31371323
4.

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 Jul 4;7(1):167. doi: 10.1186/s40425-019-0640-y.

5.

Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies.

Panni RZ, Herndon JM, Zuo C, Hegde S, Hogg GD, Knolhoff BL, Breden MA, Li X, Krisnawan VE, Khan SQ, Schwarz JK, Rogers BE, Fields RC, Hawkins WG, Gupta V, DeNardo DG.

Sci Transl Med. 2019 Jul 3;11(499). pii: eaau9240. doi: 10.1126/scitranslmed.aau9240.

PMID:
31270275
6.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review. Erratum in: J Immunother Cancer. 2019 Jul 4;7(1):167.

7.

Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.

Jiang H, Liu X, Knolhoff BL, Hegde S, Lee KB, Jiang H, Fields RC, Pachter JA, Lim KH, DeNardo DG.

Gut. 2019 May 10. pii: gutjnl-2018-317424. doi: 10.1136/gutjnl-2018-317424. [Epub ahead of print]

PMID:
31076405
8.

Macrophages as regulators of tumour immunity and immunotherapy.

DeNardo DG, Ruffell B.

Nat Rev Immunol. 2019 Jun;19(6):369-382. doi: 10.1038/s41577-019-0127-6. Review.

PMID:
30718830
9.

Recruitment of CCR2+ tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer.

Grossman JG, Nywening TM, Belt BA, Panni RZ, Krasnick BA, DeNardo DG, Hawkins WG, Goedegebuure SP, Linehan DC, Fields RC.

Oncoimmunology. 2018 Aug 1;7(9):e1470729. doi: 10.1080/2162402X.2018.1470729. eCollection 2018.

10.

Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1.

Meyer MA, DeNardo DG.

Immunity. 2018 Apr 17;48(4):621-623. doi: 10.1016/j.immuni.2018.03.029.

11.

Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.

Meyer MA, Baer JM, Knolhoff BL, Nywening TM, Panni RZ, Su X, Weilbaecher KN, Hawkins WG, Ma C, Fields RC, Linehan DC, Challen GA, Faccio R, Aft RL, DeNardo DG.

Nat Commun. 2018 Mar 28;9(1):1250. doi: 10.1038/s41467-018-03600-6.

12.

SNAIL1 action in tumor cells influences macrophage polarization and metastasis in breast cancer through altered GM-CSF secretion.

Brenot A, Knolhoff BL, DeNardo DG, Longmore GD.

Oncogenesis. 2018 Mar 29;7(3):32. doi: 10.1038/s41389-018-0042-x.

13.

Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma.

Nywening TM, Belt BA, Cullinan DR, Panni RZ, Han BJ, Sanford DE, Jacobs RC, Ye J, Patel AA, Gillanders WE, Fields RC, DeNardo DG, Hawkins WG, Goedegebuure P, Linehan DC.

Gut. 2018 Jun;67(6):1112-1123. doi: 10.1136/gutjnl-2017-313738. Epub 2017 Dec 1.

14.

Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression.

Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, Cullinan DR, Luo J, Bearden AR, Lavine KJ, Yokoyama WM, Hawkins WG, Fields RC, Randolph GJ, DeNardo DG.

Immunity. 2017 Sep 19;47(3):597. doi: 10.1016/j.immuni.2017.08.018. No abstract available.

15.

Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression.

Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, Cullinan DR, Luo J, Bearden AR, Lavine KJ, Yokoyama WM, Hawkins WG, Fields RC, Randolph GJ, DeNardo DG.

Immunity. 2017 Aug 15;47(2):323-338.e6. doi: 10.1016/j.immuni.2017.07.014. Erratum in: Immunity. 2017 Sep 19;47(3):597.

16.

Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy.

Jiang H, Hegde S, DeNardo DG.

Cancer Immunol Immunother. 2017 Aug;66(8):1037-1048. doi: 10.1007/s00262-017-2003-1. Epub 2017 Apr 27. Review.

17.

Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.

Zhang D, Li L, Jiang H, Knolhoff BL, Lockhart AC, Wang-Gillam A, DeNardo DG, Ruzinova MB, Lim KH.

Clin Cancer Res. 2017 Apr 1;23(7):1748-1759. doi: 10.1158/1078-0432.CCR-16-1121. Epub 2016 Oct 4.

18.

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo DG.

Nat Med. 2016 Aug;22(8):851-60. doi: 10.1038/nm.4123. Epub 2016 Jul 4.

19.

Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis.

Ruhland MK, Loza AJ, Capietto AH, Luo X, Knolhoff BL, Flanagan KC, Belt BA, Alspach E, Leahy K, Luo J, Schaffer A, Edwards JR, Longmore G, Faccio R, DeNardo DG, Stewart SA.

Nat Commun. 2016 Jun 8;7:11762. doi: 10.1038/ncomms11762.

20.

The Action of Discoidin Domain Receptor 2 in Basal Tumor Cells and Stromal Cancer-Associated Fibroblasts Is Critical for Breast Cancer Metastasis.

Corsa CA, Brenot A, Grither WR, Van Hove S, Loza AJ, Zhang K, Ponik SM, Liu Y, DeNardo DG, Eliceiri KW, Keely PJ, Longmore GD.

Cell Rep. 2016 Jun 14;15(11):2510-23. doi: 10.1016/j.celrep.2016.05.033. Epub 2016 Jun 2.

21.

Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.

Ohman KA, Hashim YM, Vangveravong S, Nywening TM, Cullinan DR, Goedegebuure SP, Liu J, Van Tine BA, Tiriac H, Tuveson DA, DeNardo DG, Spitzer D, Mach RH, Hawkins WG.

Oncotarget. 2016 Jun 7;7(23):33529-41. doi: 10.18632/oncotarget.9551.

22.

Antagonizing Integrin β3 Increases Immunosuppression in Cancer.

Su X, Esser AK, Amend SR, Xiang J, Xu Y, Ross MH, Fox GC, Kobayashi T, Steri V, Roomp K, Fontana F, Hurchla MA, Knolhoff BL, Meyer MA, Morgan EA, Tomasson JC, Novack JS, Zou W, Faccio R, Novack DV, Robinson SD, Teitelbaum SL, DeNardo DG, Schneider JG, Weilbaecher KN.

Cancer Res. 2016 Jun 15;76(12):3484-95. doi: 10.1158/0008-5472.CAN-15-2663. Epub 2016 May 23.

23.

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC.

Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4.

24.

Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer.

D'Amico L, Mahajan S, Capietto AH, Yang Z, Zamani A, Ricci B, Bumpass DB, Meyer M, Su X, Wang-Gillam A, Weilbaecher K, Stewart SA, DeNardo DG, Faccio R.

J Exp Med. 2016 May 2;213(5):827-40. doi: 10.1084/jem.20150950. Epub 2016 Apr 4.

25.

Thymic stromal lymphopoietin blocks early stages of breast carcinogenesis.

Demehri S, Cunningham TJ, Manivasagam S, Ngo KH, Moradi Tuchayi S, Reddy R, Meyers MA, DeNardo DG, Yokoyama WM.

J Clin Invest. 2016 Apr 1;126(4):1458-70. doi: 10.1172/JCI83724. Epub 2016 Feb 29.

26.

Regramming myeloid responses to improve cancer immunotherapy.

Zhu Y, Hawkins WG, DeNardo DG.

Oncoimmunology. 2015 May 22;4(6):e974399. eCollection 2015 Jun.

27.

TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy.

Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park CC, Coussens LM.

Cancer Immunol Res. 2015 May;3(5):518-25. doi: 10.1158/2326-6066.CIR-14-0232. Epub 2015 Feb 25.

28.

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG.

Cancer Res. 2014 Sep 15;74(18):5057-69. doi: 10.1158/0008-5472.CAN-13-3723. Epub 2014 Jul 31.

29.

Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer.

Panni RZ, Sanford DE, Belt BA, Mitchem JB, Worley LA, Goetz BD, Mukherjee P, Wang-Gillam A, Link DC, Denardo DG, Goedegebuure SP, Linehan DC.

Cancer Immunol Immunother. 2014 May;63(5):513-28. doi: 10.1007/s00262-014-1527-x. Epub 2014 Mar 21.

30.

A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma.

Sanford DE, Porembka MR, Panni RZ, Mitchem JB, Belt BA, Plambeck-Suess SM, Lin G, Denardo DG, Fields RC, Hawkins WG, Strasberg SM, Lockhart AC, Wang-Gillam A, Goedegebuure SP, Linehan DC.

J Cancer Ther. 2013 May;4(3):797-803.

31.

Targeting tumor-infiltrating macrophages to combat cancer.

Panni RZ, Linehan DC, DeNardo DG.

Immunotherapy. 2013 Oct;5(10):1075-87. doi: 10.2217/imt.13.102. Review.

32.

Cathepsin C is a tissue-specific regulator of squamous carcinogenesis.

Ruffell B, Affara NI, Cottone L, Junankar S, Johansson M, DeNardo DG, Korets L, Reinheckel T, Sloane BF, Bogyo M, Coussens LM.

Genes Dev. 2013 Oct 1;27(19):2086-98. doi: 10.1101/gad.224899.113. Epub 2013 Sep 24.

33.

Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.

Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, Mitchem JB, Plambeck-Suess SM, Worley LA, Goetz BD, Wang-Gillam A, Eberlein TJ, Denardo DG, Goedegebuure SP, Linehan DC.

Clin Cancer Res. 2013 Jul 1;19(13):3404-15. doi: 10.1158/1078-0432.CCR-13-0525. Epub 2013 May 7.

34.

Tumor-infiltrating macrophages, cancer stem cells and therapeutic responses.

Panni RZ, Linehan DC, Denardo DG.

Oncotarget. 2012 Dec;3(12):1497-8. No abstract available.

35.

Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG.

Cancer Res. 2013 Feb 1;73(3):1128-41. doi: 10.1158/0008-5472.CAN-12-2731. Epub 2012 Dec 5.

36.

Battle over CCL2 for control of the metastatic niche: neutrophils versus monocytes.

Mitchem JB, DeNardo DG.

Breast Cancer Res. 2012 Jul 19;14(4):315. doi: 10.1186/bcr3149.

37.

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM.

Cancer Discov. 2011 Jun;1(1):54-67. doi: 10.1158/2159-8274.CD-10-0028. Epub 2011 Jun 1.

38.

MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles.

Daldrup-Link HE, Golovko D, Ruffell B, Denardo DG, Castaneda R, Ansari C, Rao J, Tikhomirov GA, Wendland MF, Corot C, Coussens LM.

Clin Cancer Res. 2011 Sep 1;17(17):5695-704. doi: 10.1158/1078-0432.CCR-10-3420. Epub 2011 Jul 26.

39.

Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression.

Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, Coussens LM, Karin M, Goldrath AW, Johnson RS.

Cancer Res. 2010 Oct 1;70(19):7465-75. doi: 10.1158/0008-5472.CAN-10-1439. Epub 2010 Sep 14.

40.

Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.

DeNardo DG, Andreu P, Coussens LM.

Cancer Metastasis Rev. 2010 Jun;29(2):309-16. doi: 10.1007/s10555-010-9223-6. Review.

41.

FcRgamma activation regulates inflammation-associated squamous carcinogenesis.

Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, Naldini L, de Visser KE, De Palma M, Coussens LM.

Cancer Cell. 2010 Feb 17;17(2):121-34. doi: 10.1016/j.ccr.2009.12.019. Epub 2010 Feb 4.

42.

Lymphocytes in cancer development: polarization towards pro-tumor immunity.

Ruffell B, DeNardo DG, Affara NI, Coussens LM.

Cytokine Growth Factor Rev. 2010 Feb;21(1):3-10. doi: 10.1016/j.cytogfr.2009.11.002. Epub 2009 Dec 11. Review.

43.

Optical imaging of the peri-tumoral inflammatory response in breast cancer.

Sista AK, Knebel RJ, Tavri S, Johansson M, DeNardo DG, Boddington SE, Kishore SA, Ansari C, Reinhart V, Coakley FV, Coussens LM, Daldrup-Link HE.

J Transl Med. 2009 Nov 11;7:94. doi: 10.1186/1479-5876-7-94.

44.

CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.

DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM.

Cancer Cell. 2009 Aug 4;16(2):91-102. doi: 10.1016/j.ccr.2009.06.018.

45.

Inflaming gastrointestinal oncogenic programming.

DeNardo DG, Johansson M, Coussens LM.

Cancer Cell. 2008 Jul 8;14(1):7-9. doi: 10.1016/j.ccr.2008.06.010.

46.

Polarized immune responses differentially regulate cancer development.

Johansson M, Denardo DG, Coussens LM.

Immunol Rev. 2008 Apr;222:145-54. doi: 10.1111/j.1600-065X.2008.00600.x. Review.

47.

Immune cells as mediators of solid tumor metastasis.

DeNardo DG, Johansson M, Coussens LM.

Cancer Metastasis Rev. 2008 Mar;27(1):11-8. Review.

PMID:
18066650
48.

Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth.

DeNardo DG, Cuba VL, Kim H, Wu K, Lee AV, Brown PH.

Mol Cell Endocrinol. 2007 Oct 15;277(1-2):13-25. Epub 2007 Jul 19.

PMID:
17825481
50.

Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha.

Seo HS, DeNardo DG, Jacquot Y, Laïos I, Vidal DS, Zambrana CR, Leclercq G, Brown PH.

Breast Cancer Res Treat. 2006 Sep;99(2):121-34. Epub 2006 Mar 16.

PMID:
16541309

Supplemental Content

Loading ...
Support Center